Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date.
PARP inhibitor
maintenance
olaparib
ovarian cancer
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2019
2019
Historique:
received:
10
09
2019
accepted:
02
12
2019
entrez:
11
1
2020
pubmed:
11
1
2020
medline:
11
1
2020
Statut:
epublish
Résumé
PARP inhibitors have shown significant promise in the treatment of ovarian cancer. Olaparib is a PARP inhibitor that has been approved for maintenance for BRCA-mutated ovarian cancer in the recurrent and front-line setting as well as for treatment of BRCA-mutated ovarian cancer in patients who have received multiple prior lines of chemotherapy. In this review, we focus on the use of olaparib in the maintenance setting including the evidence to date, ongoing research, and future directions.
Identifiants
pubmed: 31920338
doi: 10.2147/OTT.S195552
pii: 195552
pmc: PMC6938196
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
11497-11506Informations de copyright
© 2019 Montemorano et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Ann Oncol. 2018 Jun 1;29(6):1366-1376
pubmed: 29750420
Gynecol Oncol. 2014 May;133(2):362-9
pubmed: 24607283
Lancet Oncol. 2015 Jan;16(1):87-97
pubmed: 25481791
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Curr Oncol. 2007 Oct;14(5):195-208
pubmed: 17938703
Nature. 2005 Apr 14;434(7035):913-7
pubmed: 15829966
N Engl J Med. 2012 Apr 12;366(15):1382-92
pubmed: 22452356
Lancet Oncol. 2019 Apr;20(4):570-580
pubmed: 30880072
Eur J Cancer. 2016 Jun;60:49-58
pubmed: 27065456
Nat Commun. 2018 Sep 28;9(1):3970
pubmed: 30266954
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Gynecol Oncol. 2011 May 1;121(2):353-7
pubmed: 21324516
Lancet Oncol. 2014 Jul;15(8):852-61
pubmed: 24882434
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483
J Natl Compr Canc Netw. 2018 Sep;16(9):1108-1135
pubmed: 30181422
Lancet. 2015 Jul 18;386(9990):249-57
pubmed: 26002111
Nature. 2012 Jan 18;481(7381):287-94
pubmed: 22258607
Oncotarget. 2016 Mar 22;7(12):13587-98
pubmed: 26871470
Semin Oncol. 2006 Apr;33(2 Suppl 6):S12-6
pubmed: 16716798
J Clin Oncol. 2019 Nov 10;37(32):2968-2973
pubmed: 31173551
J Clin Oncol. 2019 Jun 1;37(16):1380-1390
pubmed: 31002578
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
J Ovarian Res. 2019 Jan 28;12(1):9
pubmed: 30691488
J Gynecol Oncol. 2018 Mar;29(2):e31
pubmed: 29468855
J Clin Oncol. 2015 Feb 1;33(4):340-8
pubmed: 25534386
Lancet Oncol. 2018 Dec;19(12):1680-1687
pubmed: 30413383
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Lancet Oncol. 2014 Oct;15(11):1207-14
pubmed: 25218906
N Engl J Med. 2011 Dec 29;365(26):2473-83
pubmed: 22204724
J Pathol. 2013 Feb;229(3):422-9
pubmed: 23165508
J Clin Oncol. 2015 Jan 20;33(3):244-50
pubmed: 25366685
Best Pract Res Clin Obstet Gynaecol. 2017 May;41:3-14
pubmed: 27743768
N Engl J Med. 2006 Jan 5;354(1):34-43
pubmed: 16394300